1-6 of 6
Serena Perna
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Free
Marc Hoffmann, Julio Chavez, Jason Westin, Judit Jørgensen, Javier Munoz, Cecilia Carpio, Guilherme Perini, Emmanuel Bachy, Victoria Campbell, Caroline Hasselbalch Riley, Franck Morschhauser, Daniel Morillo, Alev Akyol, Berengere De Moucheron, Michael Pourdehnad, Akshay Sudhindra, Soraya Carrancio, Jessica Voetsch, Gang Yang, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 479.
https://doi.org/10.1182/blood-2025-479
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results

Free
Grzegorz Nowakowski, Marc Hoffmann, Javier Munoz, Jason Westin, Alejandro Martin Garcia-Sancho, Michal Kwiatek, Wojciech Jurczak, Maria Bouzani, Muhamad Alhaj Moustafa, Akshay Sudhindra, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Serena Perna, Theodoros Vassilakopoulos
Journal: Blood
Blood (2025) 146 (Supplement 1): 476.
https://doi.org/10.1182/blood-2025-476
Published: 2025
Journal Articles

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

Free
Eliza Hawkes, Clementine Sarkozy, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Alex Herrera, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena Perna, Charalambos Andreadis
Journal: Blood
Blood (2025) 146 (Supplement 1): 3615.
https://doi.org/10.1182/blood-2025-3615
Published: 2025
Journal Articles

Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma

Free
Theodoros Vassilakopoulos, Javier Munoz, Huiqiang Huang, Ichiro Kawashima, Sung Yong Oh, Wojciech Jurczak, Juan Miguel Bergua Burgues, Ou Bai, Alejandro Berkovits, Keshu Zhou, Marc Hoffmann, Jason Westin, Maria Bouzani, Michal Kwiatek, Tai-Chung Huang, Argyrios Gkasiamis, Arpankumar Patel, Floriane Boucaud, Adrien Petel, Serena Perna, Grzegorz Nowakowski
Journal: Blood
Blood (2025) 146 (Supplement 1): 3704.
https://doi.org/10.1182/blood-2025-3704
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Free
Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 1006.
https://doi.org/10.1182/blood-2025-1006
Published: 2025
Journal Articles

Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process

Free
Abigail Culshaw, Frederick Arce Vargas, Gerardo Santiago Toledo, Claire Roddie, Paul Shaughnessy, Virginie Cerec, Kevin Duffy, Serena Perna, Wolfram Brugger, Michael Merges, Martin Pule
Journal: Blood
Blood (2021) 138 (Supplement 1): 477.
https://doi.org/10.1182/blood-2021-153031
Published: 2021